Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.
By O. Kolterman, John B. Buse, M. Fineman, Eling Gaines, Sonja Heintz, T. Bicsak, K. Taylor, Dennis D. Kim, M. Aisporna, Yan Wang and 1 more. Journal of Clinical Endocrinology and Metabolism, 2003
603 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/b8f7d3b19881d1bc2b2db8eb19cf12158f1ea3c6
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Molecular Biology
Citations in the corpus
- Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. (2004, background): “Dizziness 8 (7) 19 (15) 19 (15) 38 (15)”
- Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. (2008, background): “The administration of the synthetic exendin-4, a compound that binds to the GLP-1 receptor and exerts similar effects as the native GLP-1 (52), or of vildagliptin, an inhibitor of DPP-IV, the enzyme that rapidly inactivates the endogenous incretins (53;54), have been shown to reduce post-prandial gl”